Table 2.

MCTS studies using matrix-dependent approaches by cancer type.

	Matrix	Collagen	HA	Matrigel®	Alginate/Chitosan	PEG	Peptide-Based
Cancer
Glioblastoma multiforme (GBM)		U87 (bovine, isolated from spongy bone) [72]; primary (bovine, isolated from spongy bone) [72]	U87 (5 wt%, 60 kDa) [26]; D456 (5 wt%, 60 kDa) [26]	_____	U118 (1.3% w/v chitosan-PEG) [35]; U87 (1.3% w/v chitosan-PEG) [35]; U251 (2% w/v) [33]	U87 [73]	_____
Ovarian Cancer		A2780 (0.125% agarose, 10% rat tail Type I collagen, 1% alginate) [29]	_____	SKOV-3 (3% v/v, growth factor reduced) [74]	A2780 (0.125% agarose, 10% rat tail Type I collagen, 1% alginate) [29]	OV-MZ-6 (2% w/v) [39]; SKOV-3 (2% w/v) [39]	A2780 (0.5% w/v RADA16-I) [75]
Breast Cancer		MCF-7 (2% w/v sodium alginate, 1.5 mg/mL rat tail collagen type I) [34]	T47D (1.1% HA, 289 kDa) [68]; MDA-MB-231 (>106 kDa) [76]	MDA-MB-231 (2.5%) [31], (2%) [77]; BT474 (10% v/v) [65]; MDA-MB-361 (10% v/v) [65]; MCF10A (2% v/v) [77]; MCF10A-NeuN (2% v/v) [77]; MCF-7 (2% v/v) [77]	MCF-7 (2% w/v sodium alginate, 1.5 mg/mL rat tail collagen type I) [34]; MCF-7 (0.5%-2% w/v) [36]	MCF-7 [37]	MDA-MB-453S (1% w/v RADA16) [40]
Prostate Cancer		LNCaP [78] (porcine type A gelatin functionalized with methacryloyl)	LNCaP (20 mg/mL, 500 kDa) [30], PC-3 (5–10% HA-MA) [24]	LNCaP [32]	C4-2B (2, 4, 6 wt% chitosan, alginate) [79]; 22Rv1 (2, 4, 6 wt% chitosan, alginate) [79]	LNCaP (1.5% w/v) [38]; PC-3 [37]	LNCaP (1.45 mM, 5 mM and 15 mM of RADA16-I, bQ13, Q11) [32]
Colorectal Cancer		HT-29 (1.8 mg/mL, rat tail Type I collagen) [80]	_____	LOVO COLO-205 CACO-2, COLO-206F, DLD-1, HT-29, SW-480 [81]; LS174T [82]; SW1463 [82]	HCT116 (2% w/v alginate) [83]	HT29 [37]	_____
Lung Cancer		A459 (2 mg/mL) [84]	_____	344SQ (2%, growth factor reduced) [85]	_____	344SQ (10% w/v PEG-PQ, 3.5 mM RGDS) [85]	_____